Lilly Wins Stay In Zyprexa Whistleblower Suit

By Erin Marie Daly

Law360, New York (December 14, 2007, 12:00 AM ET) -- In a boost to Eli Lilly & Co., a federal judge has granted the pharmaceutical giant's bid to stay a whistleblower suit over charges it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses.

In an order handed down Thursday in the U.S. District Court for the Northern District of California, Judge Charles Breyer said that the interests of federal uniformity and judicial economy weighed in favor of a stay.

Lilly had argued that the case should be joined with a separate multidistrict product liability litigation...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles